Common Variable Immunodeficiency clinical trials
The registry lists 54 studies for Common Variable Immunodeficiency across more than 10 countries. 13 are recruiting or about to start. 27 of them are mainly about Common Variable Immunodeficiency (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.
Get an email when these change. Save the Common Variable Immunodeficiency studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
CSL Behring (5) · Bio Products Laboratory (4) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · National Cancer Institute (NCI) (4) · Paul Szabolcs (2) · Medical College of Wisconsin (1) · Grifols Therapeutics LLC (1) · Federico II University (1)
What is being tested here
Drugs under test in Common Variable Immunodeficiency studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 4
- Nov 2026Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases · Paul Szabolcs
- Dec 2026Senolytics Treatment of Interstitial Lung Disease in Common Variable Immunodeficiency · Avni Joshi
- Dec 2026Usage of Spirometry in Managing IgG Therapy in CVID With Airway Disease · University of Alabama at Birmingham
- May 2027Immunoglobulin for Hypogammaglobulinemia Due to Chimeric Antigen Receptor T Cell Therapy · University of Alberta
Who these studies take
Of the 9 Common Variable Immunodeficiency studies recruiting now, 5 (56%) set no upper age limit and 3 (33%) stop at 75 or younger. 5 (56%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 4 (44%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 5 (56%) | 5 (56%) |
| 18 | 8 (89%) | 8 (89%) |
| 30 | 9 (100%) | 9 (100%) |
| 40 | 9 (100%) | 9 (100%) |
| 50 | 8 (89%) | 8 (89%) |
| 65 | 8 (89%) | 8 (89%) |
| 75 | 7 (78%) | 7 (78%) |
| 85 | 6 (67%) | 6 (67%) |
Across all 54 studies, recruiting or not: 52% stop at 75 or younger and 22% at 65; 63% take children; 0% are for women only and 0% for men only; 22% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 11, 2026.
Results posted1
- Immune Disorder HSCT ProtocolOct 27, 2026NCT01821781
Newly registered1
Studies
Recruiting first, then most recently updated. Showing 50 of 54. Browse all 54 → or search them.
- Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of ImmunityRecruitingNCT04339777Phase 21 country
- Natural History of BronchiectasisRecruitingNCT009435141 country
- Phase 2 and 3 Placebo Controlled & Long-term Extension Study of Rilzabrutinib in Adults With iCVID to Evaluate Efficacy, Safety, and TolerabilityNot yet recruitingNCT07923305Phase 2/3
- Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary ImmunodeficienciesRecruitingNCT02579967Phase 21 country
- Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation DisordersEnrolling by invitationNCT008952711 country
- Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and HypogammaglobulinemiaRecruitingNCT06976476Phase 21 country
- Immunoglobulin for Hypogammaglobulinemia Due to Chimeric Antigen Receptor T Cell TherapyRecruitingNCT069895411 country
- Peripheral Helper T-cells in Common Variable ImmunoDeficiencyRecruitingNCT07255157Not applicable1 country
- Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung DiseaseRecruitingNCT04925375Phase 21 country
- IVIG Boya: Safety, Efficacy, and PharmacokineticsNot yet recruitingNCT06150833Phase 3
- Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)RecruitingNCT07284641Phase 21 country
- Usage of Spirometry in Managing IgG Therapy in CVID With Airway DiseaseRecruitingNCT05193552Phase 41 country
- Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency DiseasesEnrolling by invitationNCT01852370Phase 1/21 country
- Immune Disorder HSCT ProtocolCompletedNCT01821781Phase 21 country
- Leniolisib for Immune Dysregulation in CVIDCompletedNCT06897358Phase 23 countries
- Senolytics Treatment of Interstitial Lung Disease in Common Variable ImmunodeficiencyActive, not recruitingNCT05593588Phase 21 country
- Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune DeficienciesActive, not recruitingNCT01652092Not applicable1 country
- Prediction of Portal Hypertension in Patients With CVID (CVID-pHT)CompletedNCT061451001 country
- Improving the Diagnosis of Common Variable Immune DeficiencyCompletedNCT033356051 country
- Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or DysregulationActive, not recruitingNCT03663933Phase 21 country
- Severe PID With Lymphoproliferation and NeutropeniaCompletedNCT03427593Not applicable1 country
- Bronchiectasis Prevalence in Patients With Primary Humoral Immunodefiency in Champagne-Ardenne Region, FranceCompletedNCT06355323Not applicable1 country
- COVID-19 Vaccine Responses in PIDD SubjectsActive, not recruitingNCT053214071 country
- Lymphocyte Immunophenotyping in Common Variable ImmunodeficiencyCompletedNCT011967021 country
- Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell TransplantationCompletedNCT03513328Phase 1/21 country
- Study of Efficacy of CDZ173 in Patients With APDS/PASLICompletedNCT02435173Phase 2/39 countries
- Composition and Function of Gut Microbiota in Porto-sinusoidal Vascular Disease Associated With Variable Common ImmunodeficiencyStatus unknownNCT054815541 country
- A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG InfusionsCompletedNCT03576469Phase 41 country
- Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease in Patients With Common Variable ImmunodeficiencyWithdrawnNCT02789397Phase 2
- Breadth of Donor Options for People With Inherited Diseases Requiring Allogeneic Hematopoietic Stem Cell Transplant in the Era of Alternative Donor Transplants Using Post-Transplantation CyclophosphamideCompletedNCT031884191 country
- Gamma Globulin Observations and Outcomes Database for Patients With Primary Immunodeficiency Disease (GOOD-SHEPARD-PI)TerminatedNCT018839211 country
- Immune System and Gut Abnormalities in Patients With Common Variable Immunodeficiency With and Without Gastrointestinal SymptomsCompletedNCT000154311 country
- Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency DiseasesCompletedNCT01884311Phase 31 country
- The Impact of Exercise on Stress, Fatigue, and Quality of Life in Individuals With Primary Immunodeficiency DiseaseCompletedNCT03211689Not applicable1 country
- GLILD Diagnosed in Children and Young Adults With Common Variable ImmunodeficiencyStatus unknownNCT036485671 country
- Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and OlderTerminatedNCT02960399Not applicable1 country
- Human IgGs and Endothelial Function in Vivo in HumansCompletedNCT03534479Not applicable1 country
- Studies of Disorders in Antibody Production and Related Primary Immunodeficiency StatesTerminatedNCT002665131 country
- STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable ImmunodeficiencyCompletedNCT00263237Phase 11 country
- Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency DiseasesCompletedNCT01963143Phase 33 countries
- "Prime Boost" Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable ImmunodeficiencyTerminatedNCT01489618Phase 21 country
- The Rifaximin Study in CVIDCompletedNCT01946906Phase 41 country
- Randomized Study of Polyethylene-Glycol-Conjugated Interleukin 2 in Patients With Common Variable ImmunodeficiencyCompletedNCT00004695Not applicable
- A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary ImmunodeficiencyCompletedNCT01289847Phase 43 countries
- A Clinical Study of Intravenous ImmunoglobulinCompletedNCT00468273Phase 32 countries
- Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary ImmunodeficiencyCompletedNCT00520494Phase 44 countries
- Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.CompletedNCT00278954Phase 31 country
- Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)CompletedNCT00322556Phase 31 country
- Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)CompletedNCT00168025Phase 3
- Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement TherapyCompletedNCT00542997Phase 39 countries